VRC07 Antibody CD4 Binding Site Affinity and Self-Reactivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for HIV infection lack effective broadly neutralizing antibodies that can inhibit a wide range of HIV strains without increasing self-reactivity, limiting their therapeutic potential.
Innovation Solution
Development of the VRC07 monoclonal antibody, which binds to the CD4 binding site of HIV's gp120 protein with increased affinity and low self-reactivity, and its variants, optimized through specific amino acid substitutions in the heavy and light chains, enhancing binding capabilities while maintaining low immunogenicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If broadly neutralizing antibodies are developed to neutralize a large panel of HIV viruses, then neutralization potency is improved, but self-reactivity increases
Solution Approach 1:
The patent applies local quality by making specific amino acid substitutions only in certain regions of the antibody molecule (framework regions and specific CDR positions) while maintaining the overall structure. This allows the antibody to achieve broad neutralization potency against diverse HIV strains while controlling self-reactivity through localized modifications rather than global changes to the antibody structure.
Solution Approach 2:
The patent utilizes parameter changes by systematically modifying amino acid sequences at specific positions (framework regions and CDRs) to optimize the balance between neutralization potency and self-reactivity. Through controlled changes in sequence parameters and structural conformation, the antibody achieves enhanced breadth of neutralization while maintaining safety profiles.
2Reliability
If binding affinity for gp120 is increased to enhance neutralization, then neutralization potency is improved, but immunogenicity increases
Solution Approach 1:
The patent applies local quality by implementing amino acid substitutions at specific localized positions within the antibody sequence (framework regions and selected CDR positions) rather than throughout the entire molecule. This enables enhancement of gp120 binding affinity through targeted local modifications while minimizing overall immunogenicity by preserving the human-like character of the majority of the antibody sequence.
Solution Approach 2:
The patent employs parameter changes by systematically adjusting amino acid composition at specific positions to optimize binding affinity while controlling immunogenicity. Through controlled modifications of sequence parameters at key positions and preservation of human framework regions, the antibody achieves high neutralization potency with reduced immunogenicity compared to fully non-human antibodies.
Data Source
AI summary
Monoclonal neutralizing antibodies that specifically bind to HIV-1 gp120 and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV infection is disclosed.